Centrient is the new name

DSM Sinochem Pharmaceuticals has new identity under private equity owner

Singapore-based DSM Sinochem Pharmaceuticals (DSP) has been renamed Centrient Pharmaceuticals with effect from 10 December. This follows the completion in October of its sale from the joint ownership of DSM and the Sinochem Group to Bain Capital Private Equity.

 

“The name Centrient emphasises the way in which we operate: putting our brand promise of ‘Quality, Reliability and Sustainability’ at the centre of everything we do,” said CEO Karl Rotthier. “Our bold and creative new name and logo showcase our company as one which prides itself on being at the centre of modern healthcare, through our life-saving APIs and finished dosage forms.”

 

DSP was originally formed in 2011 as a 5-50 joint venture. In 2017, it had sales of about €440 million, with manufacturing sites and sales offices in China, India, the Netherlands, Spain, the US and Mexico, employing some 2,000 people. It makes pharmaceutical intermediates, APIs and finished dosage forms, with particularly strengths in beta-lactam antibiotics, statins and anti-fungals.

 

The company will also adopt a corporate brand identity and website. It stated that it “will provide further updates to customers, suppliers and partners regarding these changes to ensure a smooth transition in the implementation of the new name”.